Close Menu
    What's Hot

    Longevity & Mortality Investor Conference 2026

    May 19, 2026

    Leeds Building Society Staff Pension Scheme Completes Bulk Purchase Annuity Buy-In With Royal London

    May 18, 2026

    International Life Settlement Forum 2026

    May 18, 2026
    X (Twitter) LinkedIn
    Longevity & Mortality Investor
    • Home
    • Coverage
      1. Life Insurance Capital Solutions
      2. Life Insurance
      3. Longevity and Mortality Risk Transfer
      4. Mortality
      5. Secondary Life Markets
      6. View All

      Will the US Asset Intensive Life Reinsurance Market Continue Recent Growth Spurt?

      April 22, 2026

      Daiichi Life to Reinsure Whole Life Block with Prismic Life

      April 13, 2026

      Reporting Change to Provide Regulators With More Transparency into US/Offshore Asset-Intensive Life Reinsurance Treaties

      January 28, 2026

      Capital Markets Investors Could Be About to Get a Slice of UK Life Insurance Risk

      November 26, 2025

      Chronic Disease Onset and Cumulative Exposure: Clinical, Prognostic and Underwriting Implications

      May 13, 2026

      US Annuity Sales Notch Tenth Consecutive $100bn+ Quarter

      May 11, 2026

      Life Settlement Secondary Market Returns to Growth but Plenty of Untapped Potential Still Remains

      April 22, 2026

      EIOPA Sets Out Views on Private Equity Ownership of Life Insurers in New Consultation Paper

      March 25, 2026

      Leeds Building Society Staff Pension Scheme Completes Bulk Purchase Annuity Buy-In With Royal London

      May 18, 2026

      Too Early To Judge Impact of New Funded Reinsurance Rules on UK Pension Risk Transfer Market

      May 13, 2026
      Just Group

      Safe Computing Pension Fund Completes Bulk Purchase Annuity Buy-In With Just Group

      May 11, 2026

      Bakkavor Pension Scheme Completes Bulk Purchase Annuity Buy-In With Rothesay

      May 5, 2026

      Pricing in the Unknown: Why Mortality Models Aren’t Ready for MCED Tests Just Yet

      April 9, 2026

      Better Understanding of Alzheimer’s Is Improving Lives if Not Actuarial Assumptions – Yet

      March 25, 2026

      Business as Usual in UK Pension Risk Transfer Market Amid Record Low Mortality in England and Wales

      March 25, 2026

      Latest CMI Model Shows Further Rise in Cohort Life Expectancy

      March 11, 2026

      LISA Files Amicus Brief Highlighting Consumer Impact of Adverse Ruling Regarding Term Life Insurance Policies

      May 18, 2026

      Proprietary Reverse Mortgage Market Growth a Welcome Development for MBS Investors

      May 13, 2026

      Two Years On, PHL Variable Saga Approaches Conclusion

      May 13, 2026

      UK Equity Release Market Origination Slows To Begin 2026

      May 6, 2026

      Longevity & Mortality Investor Conference 2026

      May 19, 2026

      Leeds Building Society Staff Pension Scheme Completes Bulk Purchase Annuity Buy-In With Royal London

      May 18, 2026

      International Life Settlement Forum 2026

      May 18, 2026

      LISA Files Amicus Brief Highlighting Consumer Impact of Adverse Ruling Regarding Term Life Insurance Policies

      May 18, 2026
    • Events
    • Latest Issues

      Editor’s Letter – Volume 2, Issue 5, May 2026

      May 13, 2026

      Editor’s Letter – Volume 2, Issue 4, April 2026

      April 9, 2026

      Editor’s Letter – Volume 2, Issue 3, March 2026

      March 11, 2026

      Editor’s Letter – Volume 2, Issue 2, February 2026

      February 11, 2026

      Editor’s Letter – Volume 2, Issue 1, January 2026

      January 14, 2026
    • Contact Us
    Newsletter
    Longevity & Mortality Investor

    Innovating Beyond Cardiology: Discoveries in Acquired Chronic Muscle Spasm and Resulting Chronic Pain

    Mortality June 14, 2024By Dr. Roger H. Coletti
    Medical technology
    Share
    Twitter LinkedIn Email

    One of the most common ills of mankind is chronic pain. In some cases, the associated chronic muscle spasm is known to be the culprit.  

    However, in some cases there is not an obvious connection between the pain and the chronic muscle spasm that was responsible for the chronic pain. In any case, treatment of chronic pain requires knowledge of its source. If chronic muscle spasm is indeed the source, then it is necessary to have a diagnostic tool to identify the muscle or muscles in chronic spasm.  

    Ultimately, a treatment that specifically targets chronic muscle spasm is then needed to successfully treat the chronic pain.   

    What is not generally known is that muscles in chronic spasm are very electrically active. Use of an EMG device, that is essentially an EKG for muscle, is all that is needed to identify a muscle in chronic spasm. Unlike EKG devices, a needle must be inserted into the muscle to record the electrical activity.  

    Surface recordings of EMG are possible but only tell of generalised electrical activity and do not identify specific muscles. When treatment of muscles in chronic spasm involves an injection technique, not only the specific muscle but all segments of the muscle demonstrating enhanced electrical activity need to be identified.  

    Successful treatment by injection will result in elimination of the enhanced electrical activity. Medications such as Botox have a slow onset and the results peak at about two weeks. Medication combinations such as Lidocaine/Phenoxybenzamine have an initial immediate effect of resolution of the enhanced electrical activity and a secondary effect that can last for months.  

    When Lidocaine is utilised, it is possible to map the entire muscle and verify that all parts of the muscle that demonstrated enhanced electrical activity have been treated and adequately suppressed.   

    Getting back to basics, muscles in chronic spasm can cause pain at a distance. One of the most obvious examples is a condition called IT band syndrome which causes knee pain. The muscle that is responsible is the tensor fascia lata, which is a relatively small muscle in the upper anterior thigh.  

    Resolution of spasm of that muscle results in near immediate relief of the knee pain. On the other hand, pain resulting from some muscles in chronic spasm results in local pain such as in shin splints that are caused by muscles in the anterior leg below the knee.   

    There has been significant controversy regarding the origin of the enhanced electrical activity in various states of muscle activity. However, relative to identification and treatment, the exact origin is of little consequence.  

    Prolonged elimination of the enhanced electrical activity, that is identified in the scientific literature as Spontaneous Electrical Activity or SEA, results in resolution of the chronic spasm and sustained relief of chronic pain if it was secondary to the chronic muscle spasm.   

    If it can be identified that a muscle is in chronic spasm and appears to be the source of chronic pain, then treatment of the chronic muscle spasm and not suppression of the chronic pain with pain medications such as opioids should be focus of treatment. A treatment protocol named Coletti Method Emg ChemoDenervation (CMECD) has been shown in somewhat limited but statistically significant clinical setting to relieve chronic pain by prolonged suppression of the SEA.  

    Fortunately, when this protocol is utilised, the SEA does not return, nor does the muscle spasm or the resulting chronic pain.  

    The question remains: how does the muscle go into chronic spasm in the first place?  

    What I have postulated is that what is seen in cardiac muscle during a state of contraction is that the contraction of the muscle limits the blood supply that is needed for relaxation of the muscle. It turns out that the muscle needs more blood supply and therefore energy to relax than to contract. It is like a mouse trap, much more effort to set the trap than to set it off.  

    Normally, a muscle in spasm does not stay in spasm long enough to limit the energy supply to relax. But if an acquired muscle spasm from an overuse injury is not attended to, then the spasm sets off a chain of events that leads not only to chronic spasm but a degeneration of the muscle with loss of mitochondria and muscle fibers.  

    Recovery requires significant time with unimpeded blood supply for new mitochondria to emerge and repair of the muscle fibres. Short-term relief of chronic muscle spasm does not suffice and thus a therapy that has a long-term solution is necessary.  

    Alternatively, a therapy performed on a daily basis for months may be sufficient. It is likely that there are a number of therapies that may suffice but will require very frequent applications for at least two-three months depending upon the degree of injury and loss of cellular elements resulting from the prolonged ischemia, ie: poor blood supply.   

    I had done research during my cardiology followship that unfortunately was not reported. The findings were that the blood flow during cardiac contraction that is known to be less than during cardiac relaxation can be altered by medications that limit the force of cardiac contraction.  

    At a certain point of suppression of cardiac contraction, the predominant cardiac blood supply to the cardiac tissue is predominantly in a state of cardiac contraction. This demonstrates that muscle contraction limits the blood supply.   

    Now to the question of the SEA. Where did that come from?  

    Let’s first look at the cardiac situation. When there is poor blood supply, we get cardiac arrhythmias. The skeletal muscle is no different. The technical issues are a matter of future research, but the end result is the SEA not only identifies the presence of chronic muscle spasm but is actually the ongoing cause of the chronic spasm. The SEA is like an electrical stimulator, constantly depolarising the skeletal muscle and keeping it in a state of constant contraction, limiting its blood supply and resulting in an unending state of contraction. I call it the black hole of muscle pathophysiology.   

    So, what does this newfound knowledge do for us? To start with, it provides us with a method of identifying muscle in true chronic spasm. With that knowledge, we are able to seek alternative treatments to resolve the chronic spasm and we have the means to verify success or failure of those treatments.   

    The CMECE procedure is one proven way to treat chronic muscle spasm and resultant chronic pain secondary to chronic muscles spasm. It can be performed by any medical professional that is allowed to do intramuscular injections and has minimal risk. Cost is also relatively minimal with a one-time procedure, all that is necessary, likely to be under $500 for all costs incurred.   

    Other procedures should be able to be developed given the understanding of the cause of chronic muscle spasm and may not require injection of any medication. Hopefully, these treatments will emerge. In the meantime, the CMECD procedure is available to be performed worldwide and holds the opportunity to relieve chronic pain in a large portion of those with chronic pain.   

    Dr Roger H. Coletti is Medical Director at Fasano Underwriting, a Longevity Holdings company


    Any views expressed in this article are those of the author(s) and do not necessarily reflect the views of Life Risk News or its publisher, the European Life Settlement Association

    2024 - June Clinical Mortality Commentary Volume 3 Issue 6 -June 2024
    Share. Twitter LinkedIn Email

    Related Posts

    Chronic Disease Onset and Cumulative Exposure: Clinical, Prognostic and Underwriting Implications

    May 13, 2026By Dr. Jyotsna Kamble

    Pricing in the Unknown: Why Mortality Models Aren’t Ready for MCED Tests Just Yet

    April 9, 2026By Mark McCord

    Better Mortality Analytics Will Unlock the Next Phase of Life Settlement Growth

    April 9, 2026By Liam Bodemeaid

    Better Understanding of Alzheimer’s Is Improving Lives if Not Actuarial Assumptions – Yet

    March 25, 2026By Mark McCord
    Latest Issue

    Too Early To Judge Impact of New Funded Reinsurance Rules on UK Pension Risk Transfer Market

    May 13, 2026

    Proprietary Reverse Mortgage Market Growth a Welcome Development for MBS Investors

    May 13, 2026

    Two Years On, PHL Variable Saga Approaches Conclusion

    May 13, 2026

    Chronic Disease Onset and Cumulative Exposure: Clinical, Prognostic and Underwriting Implications

    May 13, 2026
    Ad

    Where Longevity and Mortality Meet the Markets
    ISSN 2978-5219

    X (Twitter) LinkedIn
    Coverage
    • Life Insurance Capital Solutions
    • Life Insurance
    • Longevity and Mortality Risk Transfer
    • Mortality Risk
    • Secondary Life Markets
    More Info
    • Home
    • About Us
    • Contact Us
    • Guest Articles
    • Submit Story Idea
    Our Newsletter
    Get the latest industry news, commentary and events from the Longevity & Mortality Investor directly into your inbox. Why not sign up today?

    © 2026 Longevity & Mortality Investor. Website by Kavells.
    • Sitemap
    • Privacy Policy
    • Copyright Notice
    • Terms & Conditions

    Type above and press Enter to search. Press Esc to cancel.